Item 8.01. Other Events.
On April 9, 2021, CM Life Sciences III Inc. (the "Company") consummated its
initial public offering (the "IPO") of 55,200,000 units (the "Units"), including
the issuance of 7,200,000 Units as a result of the underwriters' exercise in
full of its over-allotment option. Each Unit consists of one share of Class A
common stock of the Company, par value $0.0001 per share ("Class A Common
Stock"), and one-fifth of one redeemable warrant of the Company (each, a
"Warrant"), with each whole Warrant entitling the holder thereof to purchase one
share of Class A Common Stock for $11.50 per share, subject to adjustment. The
Units were sold at a price of $10.00 per Unit, generating gross proceeds to the
Company of $552,000,000.
On April 9, 2021, simultaneously with the consummation of the IPO, the Company
completed the private sale (the "Private Placement") of an aggregate of
8,693,333 warrants (the "Private Placement Warrants") to CMLS Holdings III LLC
and the Company's independent directors (and/or entities controlled by them) at
a purchase price of $1.50 per Private Placement Warrant, generating gross
proceeds to the Company of $13,040,000.
A total of $552,000,000, comprised of $540,960,000 of the proceeds from the IPO
(which amount includes $19,320,000 of the underwriters' deferred discount) and
$11,040,000 of the proceeds of the sale of the Private Placement Warrants, was
placed in a U.S.-based trust account at J.P. Morgan Chase Bank, N.A. maintained
by Continental Stock Transfer & Trust Company, acting as trustee.
An audited balance sheet as of April 9, 2021 reflecting receipt of the proceeds
upon consummation of the IPO and the Private Placement has been issued by the
Company and is included as Exhibit 99.1 to this Current Report on Form 8-K.
© Edgar Online, source Glimpses
CM LIFE 
